Vectus Biosystems Ltd banner

Prices of ASX stocks are not being updated. The latest VBS price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.

Intrinsic Value

The intrinsic value of Vectus Biosystems Ltd (VBS) under the Base Case is 0.016 AUD per share. Compared with the last price of 0.105 AUD on Oct 14, the stock appears Overvalued by 84% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

VBS Intrinsic Value
AU$0.016
Overvaluation 84%
Intrinsic Value
Price AU$0.105
Alert me when VBS is below its intrinsic value
Today AU$0.013 · 87.5% below the current price

VBS is more expensive than usual. It was this expensive or more expensive on just 24% of days in the past 5 years.

Alternatives to VBS

Fundamental Analysis

What Vectus Biosystems Does

Biotechnology Health Care

Vectus Biosystems Ltd. is a drug discovery and development company, which engages in the treatment for fibrosis and high blood pressure, which includes therapeutics for diseases in the fibrotic market namely heart, kidney, and liver disease. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm focuses on medical research and development. The company is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases.

Headquarters
Australia AU
IPO date
Feb 23, 2016
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue VBS Research

Decided on Vectus Biosystems? Get an email when VBS reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one VBS stock?

The intrinsic value for Vectus Biosystems Ltd (VBS) under the Base Case is 0.016 AUD.

Is VBS stock undervalued or overvalued?

Compared with the last price of 0.105 AUD on Oct 14, the stock appears Overvalued by 84% .

How reliable are our estimates? See how past valuations played out
Back to Top